Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy

Journal of Thoracic Oncology

Volumn 1, Issue 6, 2006, Pages 545-550

  Chen, Yuh Min ^a,b,c   Perng, Reury Perng ^a   Shih, Jen Fu ^a   Tsai, Chun Ming ^a   Whang Peng, Jacqueline ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gefitinib; Gemcitabine; Non small cell lung cancer; Salvage therapy; Taxanes

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PACLITAXEL; QUINAZOLINE DERIVATIVE; TAXOID;

ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHINESE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PROBABILITY; PROGNOSIS; RISK FACTOR; SURVIVAL; TAIWAN; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROBABILITY; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TAIWAN; TAXOIDS; TREATMENT OUTCOME;

EID: 34247855995     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200607000-00008     Document Type: Article

References (20)

1. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004;22:330-353.
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
5. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2006;353:123-132.
6. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
7. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
8. Chen YM, Perng RP, Tsai CM, et al.Clinical experience of single-agent gemcitabine chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. J Chin Med Assoc 2005;68:163-166.
9. Chen YM, Lee CS, Lin WC, et al. Phase II study with vinorelbine and cisplatin in advanced non-small cell lung cancer failing previous chemotherapy. J Chin Med Assoc 2003;66:241-246.
10. Chen YM, Perng RP, Lee CS, et al. Phase II study of gemcitabine and vinorelbine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2003;26:567-570.
11. Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002;25:509-512.
12. Chen YM, Shih JF, Lee CS, et al. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy containing paclitaxel or not. Lung Cancer 2003;39:209-214.
13. Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031-1038.
14. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J Chemother 2005;17:679-684.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
16. Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999;17:2081-2085.
17. Gridelli C, Perrone F, Gallo C, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non-small-cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999;19:4535-4538.
18. Evans WK, Kocha W, Gagliardi A, et al. The use of gemcitabine in non-small-cell lung cancer. Cancer Prev Control 1999;3:84-94.
19. Ramlau R, Gervais R, Krzakowski M, et al. Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel. Proc Am Soc Clin Oncol 2005;23:a7017.
20. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.